Q-Line Biotech IPO

Initial public offer of upto 70,53,200 equity shares of face value of Rs. 10/- each (the equity shares) of Q-Line Biotech Limited (the company or QLBL or the issuer) at an issue price of Rs. [] per equity share (including share premium of Rs.[] per equity share) for cash, aggregating up to Rs.[] crores (public issue) out of which [] equity shares of face value of Rs. 10/- each, at an issue price of Rs. [] per equity share for cash, aggregating Rs. [] crores will be reserved for subscription by the market maker to the issue (the market maker reservation portion). The public issue less market maker reservation portion i.e. issue of [] equity shares of face value of Rs. 10/- each, at an issue price of Rs. [] per equity share for cash, aggregating upto Rs. [] croresis herein after referred to as the net issue. The public issue and net issue will constitute [] % and [*] % respectively of the post- issue paid-up equity share capital of the company. The company, in consultation with the book running lead managers, may consider a pre-ipo placement of up to 8,00,000 equity shares for cash consideration (pre-ipo placement) prior to filing of the pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the book running lead managers. If the pre-ipo placement is undertaken, the number of equity shares issued pursuant to the pre-ipo placement shall be reduced from the issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) rules, 1957, as amended (scrr). The price band and the minimum bid lot will be decided by the company.